Every claim, every source.

This 2025 systematic review specifically addresses how intermittent fasting affects fertility and reproductive hormones in women with polycystic ovary syndrome (PCOS) — the most common endocrine disorder of reproductive-aged women, characterized by hyperandrogenism, insulin resistance, and menstrual irregularity. The authors synthesized three included studies of time-restricted feeding (TRF) and related IF protocols in PCOS patients. The findings were notably favorable. Menstrual regularity improved in 33–40 percent of participants — meaning a third or more of women with previously irregular cycles reported normalized cycling after TRF intervention. Hormonal changes pointed in the right direction for the PCOS phenotype: total testosterone fell about 9 percent, free androgen index dropped 26 percent, sex hormone-binding globulin rose, and anti-Müllerian hormone and luteinizing hormone both decreased. The review concludes that intermittent fasting, particularly time-restricted feeding, shows potential as a non-pharmacological adjunct intervention for improving reproductive health and fertility in women with PCOS by addressing the core pathophysiological mechanisms (insulin resistance, hyperandrogenism) that drive the syndrome.

This Nutrients review is the first to synthesize specifically what human trials of intermittent fasting (not animal work, not religious fasting) show about sex-hormone shifts in women and men. The authors identified seven human trials total: five testing time-restricted eating, one testing a 5:2 protocol, and one studying meal timing. Their headline findings for premenopausal women with obesity: intermittent fasting reduces testosterone and the free androgen index, and increases sex hormone-binding globulin — particularly when the eating window is restricted to earlier in the day. Estrogen, luteinizing hormone, and follicle-stimulating hormone showed no statistically meaningful change in the trials reviewed. In men, intermittent fasting reduced total and free testosterone in some studies, with implications for libido and lean-mass maintenance that the authors flag as concerning at longer protocol durations. The honest summary: female reproductive hormone effects are real but modest, mostly favorable for PCOS-spectrum profiles, and depend heavily on eating-window timing.

This meta-analysis pooled 7 randomized diet-controlled interventional studies of intermittent fasting in adults with type-2 diabetes (338 total participants, mean BMI 35.7, baseline HbA1c 8.8 percent) to ask the headline question: does IF beat standard caloric-restriction diets for T2D? The answer was nuanced. Intermittent fasting produced significantly more weight loss — about 1.9 kg more than standard diet over comparable durations, with the effect strongest in heavier participants and shorter studies. But the HbA1c effect was a wash: IF was not associated with any further HbA1c reduction beyond what a standard diet achieved (point estimate −0.11 percent, confidence interval crossing zero). Other glycemic markers (fasting glucose, insulin) showed mixed results without clear superiority for either approach. The honest synthesis: at the IF protocols typically studied (mostly 16:8 time-restricted eating, some 5:2 alternate-day patterns), IF helps adherence to a calorie deficit and produces more weight loss, but the metabolic improvement is mediated through weight loss, not through any unique fasting-specific mechanism.

This NEJM review summarizes evidence that intermittent fasting regimens — alternate-day fasting, time-restricted eating, and periodic multi-day fasts — engage a "metabolic switch" from glucose-derived energy to fat- and ketone-derived energy after hepatic glycogen is depleted, typically within 12–36 hours of fasting depending on the individual and the protocol. The authors argue that repeated exposure to this switch produces adaptive responses across organ systems, including improved insulin sensitivity, reduced inflammation, increased mitochondrial biogenesis, enhanced autophagy, and improved stress resistance in cells. The review compiles findings from animal models alongside the available human trials at the time of publication. The review notes that, despite preclinical signals being strong and consistent, the human evidence base is more heterogeneous: the largest gains in metabolic markers (fasting insulin, HOMA-IR, lipid profile, inflammatory markers) appear in adults with obesity or metabolic syndrome, while effects in lean, metabolically healthy individuals are smaller. The authors flag practical issues — adherence over months, the early-fast hunger and irritability phase, and the lack of long-term outcome data — as the main barriers to clinical adoption rather than safety in healthy adults.

This is the first supervised controlled-feeding trial designed specifically to isolate intermittent fasting's metabolic effects from weight loss. Men with prediabetes were enrolled in a randomized crossover trial: 5 weeks of early time-restricted feeding (eTRF — a 6-hour eating window, with the last meal before 3 p.m.), followed by 5 weeks of a control schedule (12-hour eating window), then crossover. Critically, participants were fed enough food to maintain their weight in both conditions — the eating window changed, but total energy intake did not. Even without weight loss, eTRF improved insulin sensitivity, beta-cell responsiveness, systolic and diastolic blood pressure, oxidative stress (8-isoprostane), and evening appetite. The improvements demonstrate that intermittent fasting's cardiometabolic benefits are not solely mediated by weight loss — circadian alignment of eating and the duration of the daily fasting window have independent effects. The paper has been highly influential because it isolated the eating-window mechanism from the calorie-deficit mechanism.

This is the largest published study of sustained nutritional ketosis as a T2D management strategy. The Virta Health study enrolled 349 adults with type-2 diabetes — 262 in the continuous care intervention (CCI, an app-mediated remote-care program with macronutrient guidance toward sustained nutritional ketosis) and 87 in usual care. The design was open-label and non-randomized (participants self-selected into the intervention), so it sits below DiRECT's RCT evidence in the hierarchy — but the sample is larger and the duration is longer. At one year, the intervention group's HbA1c fell from 7.6 to 6.3 percent (the threshold for diabetes remission), mean weight loss was 13.8 kg, and 94 percent of insulin users reduced or eliminated insulin therapy. Sulfonylureas were discontinued completely in the CCI group. Secondary markers improved across the board: HOMA-IR dropped 55 percent, hsCRP dropped 39 percent, triglycerides dropped 24 percent, HDL-C rose 18 percent. The usual-care arm showed no meaningful change on any of these endpoints.

DiRECT is the trial that proved type-2 diabetes is reversible through structured weight loss in routine primary care. 306 adults aged 20–65 with T2D diagnosed within the past six years and BMI 27–45 were enrolled across 49 GP practices in Scotland and Tyneside; the practices, not the patients, were randomised. The intervention had three phases: total diet replacement (an 825–853 kcal/day formula diet for 3–5 months) with diabetes and blood-pressure medications stopped, structured food reintroduction over 2–8 weeks, then long-term weight-maintenance support. At 12 months, 46% of intervention participants achieved diabetes remission (HbA1c < 6.5% off all glucose-lowering medications) compared to 4% of usual-care controls. Mean weight loss was 10 kg in the intervention arm versus 1 kg in the control arm. Remission tracked weight loss tightly: 86% of those losing ≥15 kg achieved remission, while none who gained weight did.

This randomized pilot study asked the cleanest possible head-to-head question for intermittent fasting: when matched for the goal of weight loss, does alternate-day fasting beat ordinary daily caloric restriction? Adults with obesity (BMI ≥30, age 18–55) were randomized to either zero-calorie alternate-day fasting (ADF, n=14) or moderate daily caloric restriction (CR at -400 kcal/day, n=12) for 8 weeks, followed by 24 weeks of unsupervised follow-up. The ADF arm achieved a substantially larger calculated energy deficit (about 376 kcal/day greater than CR), yet the actual weight loss was statistically indistinguishable: ADF -8.2 kg vs CR -7.1 kg over 8 weeks. Body composition, lipids, and insulin sensitivity index showed no significant between-group differences. Safety was strong — no adverse effects, 93 percent completion in the ADF arm. Twenty-four-week unsupervised follow-up showed similar weight regain in both groups, but the ADF arm trended toward more favorable lean-mass preservation. The honest conclusion: ADF is a safe and tolerable alternative to daily restriction with equivalent short-term outcomes, not a superior intervention.

This meta-analysis pooled 11 randomized controlled trials with 618 total participants to ask whether omega-3 fish oil supplements improve insulin sensitivity in adults. Across all studies and measurement methods, the answer was essentially no. The overall standardized effect size was 0.08 (95% confidence interval -0.11 to 0.28) — statistically indistinguishable from zero. One subgroup analysis was the exception. When researchers used HOMA-IR — a calculation from fasting glucose and insulin — omega-3 supplementation showed a small but statistically significant improvement (effect size 0.30, CI 0.03 to 0.58). On more direct measures of insulin sensitivity, including the euglycemic clamp, the effect was absent. The honest read: at the doses and durations studied, typically 1 to 4 grams of EPA plus DHA per day for weeks to months, omega-3 supplements do not reliably improve insulin sensitivity in adults — though a small HOMA-IR signal exists.

This 12-week randomized trial compared a carbohydrate-restricted diet (12 percent carb / 59 percent fat / 28 percent protein) with a low-fat diet (56 percent carb / 24 percent fat / 20 percent protein) in 40 adults with atherogenic dyslipidemia — the metabolic-syndrome phenotype defined by high triglycerides, low HDL, central adiposity, and insulin resistance. Both diets were calorie-restricted to similar levels. Both produced improvements, but the carbohydrate-restricted arm consistently outperformed the low-fat arm across nearly every endpoint that defines metabolic syndrome. Glucose dropped 12 percent in the carb-restricted group; insulin fell 50 percent; insulin sensitivity improved 55 percent; body weight dropped 10 percent; adiposity dropped 14 percent. The lipid panel was the most striking divergence: triglycerides fell 51 percent on carb restriction (versus a smaller drop on low-fat), HDL rose 13 percent (versus no change), and the total-cholesterol-to-HDL ratio improved 14 percent more on carb restriction. The paper's interpretation is that the metabolic syndrome is fundamentally a carbohydrate-intolerance phenotype, and that restricting carbs addresses the upstream driver more directly than restricting fat does.

This is the Cochrane Collaboration's systematic review and meta-analysis of omega-3 PUFA supplementation in adults with type 2 diabetes. Hartweg and colleagues identified 23 randomised controlled trials totalling 1,075 participants, with intervention durations up to 8 months. Omega-3 was compared against vegetable oil or placebo across the included studies. The headline findings: omega-3 supplementation in T2D meaningfully lowered triglycerides and VLDL cholesterol — the primary cardiometabolic risk factors omega-3 was theoretically expected to improve. There was a small possible signal toward higher LDL cholesterol, though the subgroup results did not reach statistical significance. Critically, glycemic control — HbA1c, fasting glucose — was not affected by omega-3 supplementation. No significant adverse effects were reported across the trials. The Cochrane verdict: omega-3 in T2D produces favorable lipid changes but does not lower blood sugar or independently treat diabetes. The intervention is safe; it is not a glycemic therapy.

This is the conceptual paper that reframed type-2 diabetes from "irreversible chronic disease" to "the result of two reinforcing fat-accumulation cycles, each of which is reversible." Roy Taylor — invited to write the paper after presenting the hypothesis at Diabetes UK's Annual Scientific Meeting — argues that excess calorie intake drives liver fat accumulation, which causes insulin resistance and overproduction of glucose by the liver, which raises insulin secretion, which drives more fat storage in the pancreas, which damages beta cells and impairs insulin secretion. The two cycles (liver fat and pancreas fat) reinforce each other, but neither is structurally permanent. Sufficient sustained negative energy balance — typically the kind achieved by very-low-calorie diets — depletes both fat depots, breaks both cycles, and restores normal glucose handling. The hypothesis predicted what the DiRECT trial (Lean 2018) and Taylor's own Counterpoint study would later demonstrate experimentally: T2D reversal is achievable through weight loss alone, in primary care, without bariatric surgery.

This 24-week randomized controlled trial enrolled 84 adults with obesity and type-2 diabetes, randomly assigning them to either a low-carbohydrate ketogenic diet (under 20 g of carbs per day, ad-libitum protein and fat) or a low-glycemic-index reduced-calorie diet (a 500 kcal/day deficit, ordinary macronutrient distribution). Of 84 enrolled, 49 completed the protocol — typical attrition for an outpatient diet trial. The headline results favored ketogenic restriction. HbA1c dropped 1.5 percentage points on the ketogenic diet versus 0.5 points on the low-GI diet (p=0.03). Weight loss was 11.1 kg on the ketogenic arm versus 6.9 kg on the low-GI arm (p=0.008). The most striking endpoint was medication change: 95 percent of ketogenic-arm participants either reduced or eliminated their diabetes medications, compared to 62 percent on the low-GI arm (p less than 0.01). HDL cholesterol improved on the ketogenic diet (+5.6 mg/dL) and was unchanged on low-GI. The trial is one of the foundational small RCTs that established sustained nutritional ketosis as a viable T2D management strategy.

This is one of the foundational human alternate-day fasting trials, and — importantly — the actual source of the famous "57 percent insulin drop" claim that circulates widely in popular fasting content. Sixteen nonobese adults (8 men, 8 women) fasted every other day for 22 days. The protocol alternated full fasting days with normal eating days. Body weight dropped 2.5 percent and fat mass dropped 4 percent over the three weeks. Resting metabolic rate did not change significantly through day 21, but respiratory quotient fell on day 22 — indicating a clear shift toward fat oxidation, with daily fat oxidation rising by 15 grams or more. Glucose and ghrelin remained essentially stable, but fasting insulin dropped 57±4 percent. Hunger on fasting days remained elevated throughout the protocol, suggesting that adaptation to alternate-day hunger patterns does not happen quickly. The paper concluded that alternate-day fasting is feasible in nonobese adults and produces substantial fat-oxidation and insulin-sensitivity shifts, but adherence is challenging.

This is one of the cleanest human studies on what fasting does to insulin sensitivity. Eight healthy young men (average age 25, BMI around 26) fasted for 20 hours every other day for 15 days. Before and after the protocol, the researchers measured insulin action with the gold-standard test in metabolic research: the euglycemic-hyperinsulinemic clamp, which directly tells you how much glucose insulin can move into tissues at a fixed concentration. After the 15-day intermittent-fasting block, insulin-mediated whole-body glucose uptake rose from 6.3 to 7.3 mg per kilogram per minute — about a 16 percent improvement, statistically significant. Adiponectin, a hormone that improves insulin signaling and tracks metabolic health, rose by more than 50 percent measured against the basal level. The men did not lose meaningful weight, so the change is not explained by fat loss. The study was the first in humans to show that intermittent fasting itself can directly improve how insulin works.

Richard Veech's 2004 review is the most-cited mechanistic argument that ketone bodies — specifically D-β-hydroxybutyrate — are not just an alternative fuel but a more efficient one in metabolic terms. Veech's central claim is that the enthalpy of D-β-hydroxybutyrate combustion is higher per unit oxygen consumed than glucose, meaning more ATP per oxygen molecule. He uses this thermodynamic observation to argue that mild ketosis may be therapeutically useful in conditions where mitochondrial efficiency is compromised: insulin resistance, neurodegeneration, ischemia, and certain rare metabolic disorders. The review covers redox state changes during ketosis (favorable shifts in NAD+/NADH), the role of free fatty acid elevation alongside ketones in ketogenic-diet states, and the activation of PPAR signaling. Veech's framing seeded the modern field of "exogenous ketones as therapy" and is widely cited in research on ketogenic diets for epilepsy, Alzheimer's disease, and traumatic brain injury. The therapeutic claims are speculative for many of the listed conditions; the underlying biochemistry is rigorous.

This elegant human experiment isolated which variable — carbohydrate restriction or energy restriction — actually drives the metabolic response to short-term fasting. Five healthy volunteers participated in a randomized crossover protocol with two arms. In the control arm, subjects fasted for 84 hours (no food, no calories). In the lipid arm, subjects underwent the same 84-hour oral fast but received an intravenous lipid emulsion to meet resting energy requirements. The key insight: fat-derived calories supply energy without supplying carbohydrate. If energy deficit were the trigger for the fasting response, the lipid arm should blunt or eliminate the metabolic shifts. If carbohydrate absence were the trigger, the lipid arm should look identical to the control fast. Klein and Wolfe found the metabolic responses were essentially identical between arms — the same rise in ketones, free fatty acids, glycerol, palmitic acid, and the same suppression of insulin. The conclusion was clean: carbohydrate restriction, not energy deficit per se, is what flips the metabolic switch into fasting mode.

This 1978 JAMA paper by Bruce Bistrian is the canonical clinical introduction of the protein-sparing modified fast (PSMF). PSMF was developed by Bistrian and George Blackburn at Harvard in the early 1970s as a safer alternative to the total-starvation diets that were popular for severe obesity at the time. The protocol replaces calories with high-quality protein — typically around 1.2 to 1.5 grams per kilogram of ideal body weight — plus vitamin and mineral supplementation, allowing the patient to remain in nutritional ketosis while preserving lean body mass much more effectively than a water-only fast. The paper synthesizes the early clinical experience with this approach: rapid weight loss with substantially less muscle loss than total fasts produced, and reasonable tolerability in supervised clinical settings. Bistrian's clinical framework — protein as the spare, total-calorie restriction, supplementation, supervision — is the framework most modern PSMF protocols and protein-led short fasts (including the Sardine Protocol's mechanism) descend from.